Pro-Inflammatory Vicious Cycle-Normalizing Biomimetic Nanoparticles to Treat Acute Respiratory Distress Syndrome

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Immunology

Background:

• Acute respiratory distress syndrome (ARDS) involves inflammation-induced reactive oxygen species (ROS) elevation, damaging lung cells and polarizing macrophages to a pro-inflammatory M1 state.
• This creates a detrimental cycle of ROS production and M1 macrophage polarization, worsening ARDS progression and limiting single-target therapies.
• Current treatments for ARDS are suboptimal due to the complex interplay of ROS and macrophage polarization.

Purpose of the Study:

• To develop a novel therapeutic strategy targeting the dual mediators of ROS and macrophage polarization in ARDS.
• To investigate the efficacy of phosphatidylserine-modified and metformin-loaded biomimetic honeycomb manganese dioxide nanoparticles (PS-HM/M NPs) in resolving ARDS-associated inflammation.

Main Methods:

• Development of PS-HM/M NPs with superoxide dismutase (SOD) and catalase (CAT)-mimetic properties to scavenge ROS.
• Incorporation of metformin to promote M1 to M2 macrophage phenotypic transition towards a pro-resolution state.
• Evaluation of the nanoparticles' therapeutic effect in an acute lung injury (ALI) mouse model.

Main Results:

• PS-HM/M NPs effectively eliminated excessive intracellular ROS due to their SOD and CAT-mimetic activities.
• Metformin facilitated the transition of alveolar macrophages (AMs) from the pro-inflammatory M1 phenotype to the pro-resolution M2 phenotype.
• The developed nanoparticles successfully interrupted the ROS-macrophage crosstalk cycle and significantly reduced inflammation in the ALI model.

Conclusions:

• The study highlights the critical role of regulating ROS-macrophage crosstalk in ARDS pathogenesis.
• PS-HM/M NPs represent a promising dual-targeting therapeutic approach for ARDS by normalizing the vicious cycle.
• This work provides a novel avenue for developing effective ARDS therapies by addressing key inflammatory mediators.